foci佛慈品牌怎么样 申请店铺

我要投票 foci佛慈在阿胶行业中的票数:110 更新时间:2025-02-23
foci佛慈是哪个国家的品牌?「foci佛慈」是 兰州佛慈制药股份有限公司 旗下著名品牌。该品牌发源于甘肃,由创始人石爱国在2016期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力foci佛慈品牌出海!通过在本页面挂载foci佛慈品牌的产品链接和联系邮箱,可以提高foci佛慈产品曝光!跨境电商爆单神器,目前只要100元/年哦~

foci佛慈怎么样

兰州佛慈制药股份有限公司是一家具有近百年制药历史的市属国有控股上市公司和“中华老字号”企业(股票代码002644)。1929年创建于上海。1956年西迁兰州。2011年上市。目前,公司已发展成为集中药材种植与加工、天然药物与保健品研发、中药现代剂型及保健食品生产销售为一体的西北地区中医药行业的骨干企业。

截止目前,公司拥有4个生产基地、1个在建的医药科技工业园和2家全资子公司。拥有总资产100912万元、净资产71823万元。现有员工1400余人,其中各类工程技术人员400余名。拥有25条生产线,全部通过国家GMP认证,本部生产线还通过澳大利亚TGA组织、日本厚生省和乌克兰产品认证局的认证。现有药品生产批准文号345个,拥有定眩丸、参茸固本还少丸等10个独家产品,1个国家中药保护品种,9项发明专利,常年生产浓缩丸、大蜜丸、片剂等11种剂型的152种中西药产品。佛慈产品以“选材地道、工艺精良、疗效确切、服用方便”享誉中外。“佛慈”牌六味地黄丸、杞菊地黄丸、桂附地黄丸、逍遥丸、香砂养胃丸等系列产品多次被评为“甘肃名牌产品”。公司产品领域不断拓展,以阿胶、本草饮品“肖助理”等为代表的大健康产品陆续上市。“佛慈”注册商标为驰名保护,“岷山”商标为国家工商总局重点保护商标,“宝炉”、“善舒”为甘肃省著名商标。公司与中国中医科学院、瑞典斯德哥尔摩大学、清华大学、甘肃中医学院等多所国内外一流科研院所建立了良好的合作关系。现有甘肃省现代中药制剂工程技术研究中心和中瑞天然植物药和保健品研究中心两个重点研发平台。在漳县、临潭等地拥有当归规范化种植基地,总种植面积近1万亩。佛慈品牌在国内外具有良好的市场基础和广泛的影响力,国际国内销售网络日益完善,产品行销全国,出口到美国、澳大利亚、日本、香港等27个国家和地区,产品国外认证数、海外商标注册数、出口覆盖面、出口品种数长期位居同行业前列,多年来名列中国中成药出口企业十强。佛慈制药是国内首家申请欧盟药品注册的企业,如果浓缩当归丸在欧盟注册成功,并通过欧盟GMP认证,佛慈产品有望以药品身份进入欧盟市场,同时借此建立中药国际化标准。近期,佛慈制药被国家商务部等部委列入国家“首批中医药服务贸易先行先试骨干企业”名单。

近三年,公司将以新区项目为依托、以构建国际国内销售网络为重点,抢抓机遇,加快发展,力争在三年内实现营业收入10亿元,其中中成药出口1000万美元的目标。

Lanzhou foci Pharmaceutical Co., Ltd. is a municipal state-owned holding listed company and "China time honored brand" enterprise with nearly a hundred years of pharmaceutical history (Stock Code: 002644). Founded in Shanghai in 1929. In 1956, it moved west to Lanzhou. Listed in 2011. At present, the company has developed into a backbone enterprise in the Northwest China traditional Chinese medicine industry, which focuses on the cultivation and processing of traditional Chinese medicine, the research and development of natural drugs and health products, the production and sales of modern dosage forms of traditional Chinese medicine and health food. Up to now, the company has 4 production bases, 1 pharmaceutical science and Technology Industrial Park under construction and 2 wholly-owned subsidiaries. It has total assets of 1009.12 million yuan and net assets of 718.23 million yuan. There are more than 1400 employees, including more than 400 engineering and technical personnel. We have 25 production lines, all of which have passed the national GMP certification. Our production lines have also passed the certification of TGA in Australia, housheng in Japan and Ukrainian product certification authority. At present, there are 345 drug production approval numbers, 10 exclusive products such as Dingxuan pill, Shenrong Guben Huanshao pill, 1 National Traditional Chinese medicine protection variety, 9 invention patents, and 152 kinds of Chinese and Western medicine products with 11 dosage forms such as concentrated pill, big honey pill and tablet. Foci products are well-known at home and abroad for "authentic material selection, excellent technology, accurate curative effect and convenient use". "Foci" brand Liuwei Dihuang pill, Qiju Dihuang pill, Guifu Dihuang pill, Xiaoyao Pill, Xiangsha Yangwei pill and other series of products have been rated as "Gansu famous brand products" for many times. The product field of the company has been expanding, and the large health products represented by donkey hide gelatin and herbal drink "Xiao assistant" have been listed in succession. "Foci" registered trademark is well-known protection, "Minshan" trademark is the key protection trademark of the State Administration for Industry and commerce, "Baolu" and "Shanshu" are famous trademarks of Gansu Province. The company has established good cooperation with many domestic and foreign first-class scientific research institutes, such as Chinese Academy of traditional Chinese medicine, Stockholm University, Tsinghua University, Gansu College of traditional Chinese medicine, etc. At present, there are two key research and development platforms: Gansu Modern Chinese medicine preparation engineering technology research center and Zhongrui natural plant medicine and health product research center. In Zhangxian County, Lintan and other places, there are standardized planting bases for angelica, with a total planting area of nearly 10000 mu. Foci brand has a good market foundation and wide influence at home and abroad. Its international and domestic sales network is increasingly improved. Its products are sold all over the country and exported to 27 countries and regions such as the United States, Australia, Japan and Hong Kong. The number of foreign certification, overseas trademark registration, export coverage and export varieties of its products have long been in the forefront of the same industry. It has been ranked in the middle of China for many years Top 10 pharmaceutical export enterprises. Fosci pharmaceutical is the first enterprise applying for EU drug registration in China. If the concentrated Angelica pill is successfully registered in the EU and passes the EU GMP certification, fosci products are expected to enter the EU market as drugs, and at the same time establish international standards for traditional Chinese medicine. Recently, foci pharmaceutical has been listed in the list of "the first batch of backbone enterprises in the first trial of TCM service trade" by the Ministry of Commerce and other ministries. In the past three years, the company will take the new area project as the support, focus on the construction of international and domestic sales network, seize the opportunity, accelerate the development, and strive to achieve the business income of 1 billion yuan in three years, including the goal of 10 million US dollars for the export of Chinese patent medicine.

本文链接: https://brand.waitui.com/f19a649a3.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

天岳先进:2024年净利润1.8亿元 同比扭亏为盈

36氪获悉,天岳先进发布业绩快报,公司2024年实现营业收入17.68亿元,同比增长41.37%;实现归属于母公司所有者的净利润1.80亿元,同比扭亏为盈。主要原因是公司大尺寸、导电型产品产能产量持续提升,销售量增加,同时产品毛利率上升。

49分钟前

小米集团卢伟冰:小米15 Ultra会是越级式的一代产品

36氪获悉,小米集团合伙人兼总裁、手机部总裁、小米品牌总经理卢伟冰发文称,小米手机未来5年高端化的目标之一,就是要在6000元+价格段实现规模化的突破,“Ultra是6K+突破的关键产品,而小米15 Ultra会是越级式的一代产品”。

49分钟前

恒瑞医药:羟乙磺酸达尔西利片联合内分泌治疗乳腺癌III期临床试验达主要终点

36氪获悉,恒瑞医药公告称,公司自主研发的羟乙磺酸达尔西利片在激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性女性乳腺癌辅助治疗的III期临床试验中,首次期中分析主要终点达到统计学显著性。研究结果显示,达尔西利联合内分泌治疗可显著降低患者复发风险,提高患者无侵袭性疾病生存期(IDFS)。公司已向国家药品监督管理局药品审评中心递交上市前沟通交流申请。该药品是公司自主研发的化学药品1类新药,是一种口服、高效、选择性的小分子CDK4/6抑制剂。

49分钟前

深圳:近期将发布人形机器人专项政策 在全市科技重大专项中安排人工智能和机器人专项

深圳市政府新闻办2月23日召开“打造最好科技创新生态和人才发展环境”主题新闻发布会。市人工智能产业办主任林毅在会上表示,深圳在人工智能和机器人领域基础雄厚、未来可期。下一步,我们将在政策、场景、创新、机器人四个方面持续发力。此外,近期我们还将发布人形机器人专项政策,通过“揭榜挂帅”等方式,对开放应用场景、突破关键技术、构建专用数据集、提升规模化制造和应用能力等予以精准支持。同时,还将在全市科技重大专项中安排人工智能和机器人专项,鼓励产、学、研、用组成创新联合体进行协同攻关。(财联社)

49分钟前

一汽大众ID.系列部分车型官降至高5.5万元

一汽-大众宣布对旗下ID.系列部分车型进行降价,最高降幅达5.5万元。此次降价活动涉及ID.4 CROZZ和ID.6 CROZZ两款车型,无门槛一口价分别为13.99万元和19.59万元起,还可叠加官方置换补贴至高1万元、国家置换补贴至高2万元。(财联社)

49分钟前

本页详细列出关于东健阿胶的品牌信息,含品牌所属公司介绍,东健阿胶所处行业的品牌地位及优势。
咨询